Gastroesophageal Reflux Disease Market Size and Share
Market Overview
| Study Period | 2019 - 2030 |
|---|---|
| Market Size (2025) | USD 6.39 Billion |
| Market Size (2030) | USD 7.78 Billion |
| Growth Rate (2025 - 2030) | 8.43% CAGR |
| Fastest Growing Market | Asia Pacific |
| Largest Market | North America |
| Market Concentration | Medium |
Major Players
*Disclaimer: Major Players sorted in no particular order Image © Mordor Intelligence. Reuse requires attribution under CC BY 4.0. |
|
Gastroesophageal Reflux Disease Market Analysis by Mordor Intelligence
The Gastroesophageal Reflux Disease Market size is estimated at USD 6.39 billion in 2025, and is expected to reach USD 7.78 billion by 2030, at a CAGR of 8.43% during the forecast period (2025-2030).
Vonoprazan’s 2024 approval signaled a decisive break from the 30-year dominance of proton pump inhibitors, and potassium-competitive acid blockers (PCABs) are now closing efficacy gaps for refractory patients. Escalating obesity, rapid population aging, and a strong correlation between metabolic syndrome and lower esophageal sphincter dysfunction sustain demand growth. Parallel ESG-driven deprescribing programs are trimming inappropriate PPI use by almost 30% while preserving safety outcomes. On the diagnostic front, AI-enabled high-resolution manometry is redefining workflow efficiency, and LINX magnetic sphincter augmentation offers effective surgical relief for medication-refractory cases. Asia-Pacific’s robust 9.87% CAGR rounds out the growth narrative, underpinned by westernizing diets and expanding healthcare infrastructure.
Key Report Takeaways
- By diagnosis, upper endoscopy held 46.76% of the Gastroesophageal Reflux Disease market share in 2024; high-resolution manometry is set to expand at 9.67% CAGR through 2030.
- By drug class, proton pump inhibitors commanded 68.52% share of the Gastroesophageal Reflux Disease market size in 2024, whereas PCABs are the fastest-growing category.
- By end user, hospitals led with 58.45% revenue share in 2024; home-care settings are projected to grow at a 10.03% CAGR to 2030.
- By distribution channel, retail pharmacies & drug stores captured 44.45% of the 2024 Gastroesophageal Reflux Disease market; online pharmacies are advancing at 11.13% CAGR.
- By geography, North America retained 35.56% share of the Gastroesophageal Reflux Disease market in 2024, while Asia-Pacific records the fastest regional CAGR at 9.87%.
Global Gastroesophageal Reflux Disease Market Trends and Insights
Drivers Impact Analysis
| Driver | (~) % Impact on CAGR Forecast | Geographic Relevance | Impact Timeline |
|---|---|---|---|
| Escalating global obesity and ageing population | +2.1% | Global, with highest impact in North America and Europe | Long term (≥ 4 years) |
| Rising OTC self-medication culture for acid-suppressants | +1.8% | North America & EU, expanding to APAC | Medium term (2-4 years) |
| Rapid uptake of potassium-competitive acid blockers (PCABs) | +2.3% | Global, led by developed markets | Medium term (2-4 years) |
| Growing adoption of magnetic sphincter augmentation (LINX) | +0.7% | North America & EU | Long term (≥ 4 years) |
| AI-enabled high-resolution manometry improving diagnosis | +0.9% | Global, concentrated in tertiary care centers | Medium term (2-4 years) |
| Corporate ESG push to curb PPI over-prescription | +0.5% | Global, strongest in regulated markets | Short term (≤ 2 years) |
| Source: Mordor Intelligence | |||
Escalating Global Obesity and Aging Population
Obesity-driven intra-abdominal pressure and age-related motility decline combine to raise GERD prevalence. Asia-Pacific countries such as Japan now confront simultaneous aging and a rise in adolescent obesity, compelling payers to integrate chronic care pathways and early diagnosis strategies. Productivity losses from untreated GERD and comorbidity management strengthen the economic rationale for preventive approaches.[1]World Journal of Gastroenterology, “Epidemiology of GERD in Aging and Obese Populations,” wjgnet.com
Rising OTC Self-Medication Culture for Acid-Suppressants
High out-of-pocket costs in liberalized health systems are pushing consumers toward OTC PPIs and alginates. Pharmacist-led screening has proven effective in preventing duplicate therapy and inappropriate chronic use. Digital symptom-tracking apps tethered to e-commerce platforms are extending self-care while preserving safety oversight. Digital health platforms increasingly integrate with OTC purchases to provide personalized guidance and symptom tracking. The trend accelerates in markets with high healthcare costs, where consumers seek cost-effective alternatives to prescription medications while maintaining treatment efficacy.
Rapid Uptake of Potassium-Competitive Acid Blockers
Vonoprazan’s reversible binding offers faster pH control than irreversible PPIs, achieving 93% healing versus 85% for lansoprazole in pivotal trials. PPI-refractory patients report near-universal healing, and a 10-year exclusivity window protects early revenues while generics prepare pipelines. Geographic expansion remains limited by regulatory approval timelines, creating first-mover advantages in approved markets.
Growing Adoption of Magnetic Sphincter Augmentation (LINX)
LINX delivers 92.7% PPI cessation and 84% quality-of-life improvement with lower complication rates than Nissen fundoplication.[2]Journal of the American College of Surgeons, “LINX Magnetic Sphincter Augmentation Outcomes,” journalacs.org Recent U.S. Medicare coverage decisions are unlocking broader reimbursement, and cost analyses show long-term savings over chronic pharmacotherapy. The technology's appeal lies in its reversibility and preservation of normal anatomy, contrasting with irreversible surgical alternatives. Cost-effectiveness studies support broader adoption, with LINX procedures demonstrating reduced long-term medical expenses compared to continued medical management.
Restraints Impact Analysis
| Restraint | (~) % Impact on CAGR Forecast | Geographic Relevance | Impact Timeline |
|---|---|---|---|
| Patent cliffs for blockbuster proton pump inhibitors (PPIs) and H2 blockers | -1.4% | Global, strongest in generic-friendly markets | Short term (≤ 2 years) |
| Increasing FDA safety alerts on chronic PPI use | -0.8% | North America & EU, expanding globally | Medium term (2-4 years) |
| Slow payer adoption of novel endoscopic therapies | -1.1% | Global, most pronounced in cost-conscious systems | Long term (≥ 4 years) |
| Supply–chain volatility in key API (omeprazole, esomeprazole) | -0.9% | Global, with highest risk in import-dependent markets | Short term (≤ 2 years) |
| Source: Mordor Intelligence | |||
Patent Cliffs for Blockbuster PPIs and H2 Blockers
Generic pantoprazole, omeprazole, and esomeprazole have compressed prices as patent shields fall; Protonix exclusivity ends in 2026 and Dexilant in 2030. Branded firms answer with lifecycle tactics, but erosion will deepen in price-sensitive regions where generics can grab share within months of launch.
Increasing FDA Safety Alerts on Chronic PPI Use
Observational studies link chronic PPI exposure to renal injury, fractures, and infection risk, prompting more safety communications and driving physician deprescribing.[3]Frontiers in Immunology, “Macrophage Dysfunction with Long-Term PPI Use,” frontiersin.org The resulting caution dampens volume growth for maintenance-dose PPIs but simultaneously paves the way for newer classes with cleaner safety profiles.
Segment Analysis
By Diagnosis: AI Transforms Traditional Endoscopy
Upper endoscopy continued to dominate with a 46.76% share of the Gastroesophageal Reflux Disease market in 2024, driven by widespread availability and clinician familiarity. Yet AI-powered analysis is streamlining lesion detection and reducing procedure time, forcing endoscopy units to integrate software upgrades. High-resolution manometry is the fastest-growing diagnostic at 9.67% CAGR, fueled by automated pattern recognition that cuts interpretation times. Capsule techniques deliver non-invasive mucosal views for patients unable to tolerate conventional scopes.
Clinical algorithm personalization is the new norm; machine learning now recommends the optimal diagnostic pathway based on symptom clusters, reducing redundant testing. SEA-HRM achieved perfect completion rates in sedation-challenged patients and is likely to convert procedural failures into diagnostic successes. MNBI reference values display regional variation—Vietnamese cohorts show a 1,500-Ohm threshold, stressing the importance of population-specific cut-offs.
Note: Segment shares of all individual segments available upon report purchase
By Drug Class: PCABs Challenge PPI Dominance
Proton pump inhibitors still represent 68.52% of the Gastroesophageal Reflux Disease market size in 2024 and grow at 8.79% CAGR, but the metric disguises early PCAB cannibalization in developed markets. H2 antagonists hang on in rapid-relief niches, while antacids and alginates retain relevance for intermittent symptoms. Vonoprazan’s launch has sparked wider PCAB pipelines; linaprazan glurate is advancing for erosive GERD with promising pharmacokinetics.
PCABs provide more stable intragastric pH with less variability than PPIs. Combination regimens pairing alginate barriers with PCABs are under investigation to target multiple acid pathways simultaneously. Generic threats, however, loom as exclusivity windows narrow post-2032.
By End User: Home Care Accelerates Through Telemedicine
Hospitals held 58.45% share of the Gastroesophageal Reflux Disease market in 2024, reflecting their role in advanced diagnostics and refractory case management. Yet virtual care adoption allows stable patients to migrate to home monitoring, pinning a 10.03% CAGR on the home-care segment. Wireless pH capsules paired with smartphone apps supply gastroenterologists with real-time data. A German tertiary center reported telemedicine adherence equal to in-person follow-ups for 35.3% of gastro cases.
Payers incentivize hybrid care to contain costs, and bundled payments now reward reduced readmission rates. Specialty clinics exploit integrated pathways, offering dietitian input and lifestyle coaching alongside pharmacologic management to keep patients out of hospitals.
Note: Segment shares of all individual segments available upon report purchase
By Distribution Channel: Digital Transformation Accelerates
Retail outlets controlled 44.45% of Gastroesophageal Reflux Disease market transactions in 2024, but online pharmacies are expanding at 11.13% CAGR as convenience and dynamic pricing sway consumer choice. LillyDirect shows how pharma can bypass intermediaries, offering coupon-less discounts directly to patients.
E-commerce ecosystems now tie medication delivery to adherence alerts, and pharmacists conduct video-based medication therapy management to curb inappropriate chronic PPI use. Hospital pharmacies remain critical for IV formulations and controlled introductions of new agents.
Geography Analysis
North America continued to command 35.56% of the Gastroesophageal Reflux Disease market in 2024, benefiting from early PCAB adoption, widespread diagnostic availability, and premium pricing. Clinical guidelines have already integrated vonoprazan for PPI-refractory erosive esophagitis, giving the region a head start in the therapeutic transition. Insurer coverage for LINX and other minimally invasive devices further strengthens procedural revenues.
Europe maintains solid growth on back of structured telehealth programs and ESG-oriented deprescribing protocols. Germany leads digital adoption with reimbursement models supporting remote high-resolution manometry interpretation. EU regulators echo FDA concerns on chronic PPI use, nudging prescribers toward step-down approaches that include H2 antagonists and alginates. Market maturity, however, tempers volume growth for legacy PPIs.
Asia-Pacific is the fastest-growing geography at 9.87% CAGR, driven by rising disposable incomes and urban dietary shifts rich in fat and sugar. China’s local manufacturing base cushions API shortages, while India’s PLI scheme is narrowing its 70% dependency on Chinese intermediates. Japan’s aging yet tech-savvy population fuels telemedicine adoption, whereas South Korea’s high smartphone penetration supports digital adherence programs. Tailored diagnostic thresholds and lower Barrett’s prevalence underscore the need for region-specific management.
Competitive Landscape
The market remains moderately concentrated: top brands such as AstraZeneca, Takeda, and Pfizer still rely on long-standing PPI portfolios, yet innovation now defines competitive leverage. Phathom’s vonoprazan sets a new acid-suppression benchmark, while Zydus acquired rights to market the agent in India under Vault to speed regional uptake. Device innovators add parallel contest: Medtronic’s LINX and Implantica’s RefluxStop widen the solution set for refractory patients.
Patent cliffs threaten incumbent revenue streams, prompting corporate moves like Eisai’s USD 99.6 million divestiture of rabeprazole rights in China to redeploy capital toward higher-growth assets. M&A is reshaping the device arena; Merit Medical’s USD 105 million acquisition of Endogastric Solutions secures access to the EsophyX Z endoscopic fundoplication platform.
AI collaborations are emerging: gastroenterology departments partner with software vendors to refine diagnostic algorithms, and biomarker developers are exploring companion tests to flag likely PPI non-responders. Competitive intensity will hinge on an ability to validate cost-effectiveness under payer scrutiny and to secure supply chain resilience for critical APIs.
Gastroesophageal Reflux Disease Industry Leaders
-
Johnson & Johnson
-
Takeda Pharmaceutical Company Limited
-
SRS Life Sciences
-
Haleon
-
Pfizer Inc.
- *Disclaimer: Major Players sorted in no particular order
Recent Industry Developments
- April 2025: Implantica AG reported German real-world results for the RefluxStop device, emphasizing anatomical restoration without esophageal compression.
- March 2025: Eisai sold Chinese rights to rabeprazole (Pariet) to Beijing Peak Biology for JPY 15.7 billion (USD 99.6 million) and kept a milestone clause.
- March 2025: Eisai obtained Japanese approval to switch Pariet S 10 mg to OTC status, expanding consumer access.
- August 2024: Pfizer secured FDA approval for Protonix I.V. for up to 10 days of adult EE treatment and 7 days in pediatric patients ≥ 3 months.
- July 2024: Zydus Lifesciences licensed vonoprazan from Takeda to launch Vault for GERD treatment in India.
Research Methodology Framework and Report Scope
Market Definitions and Key Coverage
Our study defines the gastroesophageal reflux disease (GERD) market as the global spending on prescription and over-the-counter pharmacologic therapies, primarily proton-pump inhibitors, H2 receptor antagonists, potassium-competitive acid blockers, antacids, alginates, and selected pro-kinetics used to relieve or prevent pathologic reflux of gastric contents into the esophagus. GERD prevalence-based demand, supported by treatment days and average selling prices, sets the value baseline.
Scope exclusion: Devices and surgical procedures such as fundoplication systems, LINX implants, or diagnostic manometry kits sit outside this sizing.
Segmentation Overview
- By Diagnosis
- Upper Endoscopy
- Ambulatory pH & Impedance Monitoring
- Esophageal & High-Resolution Manometry
- Capsule Endoscopy
- Others
- By Drug Class
- Proton Pump Inhibitors (PPIs)
- H2-Receptor Antagonists
- Potassium-Competitive Acid Blockers (PCABs)
- Antacids and Alginates
- Prokinetics and Others
- By End User
- Hospitals
- Speciality Centers and Clinics
- Home-Care Settings
- By Distribution Channel
- Hospital Pharmacies
- Retail Pharmacies & Drug Stores
- Online Pharmacies
- Other Distribution Channel
- By Geography
- North America
- United States
- Canada
- Mexico
- Europe
- Germany
- United Kingdom
- France
- Italy
- Spain
- Rest of Europe
- Asia-Pacific
- China
- Japan
- India
- Australia
- South Korea
- Rest of Asia-Pacific
- Middle East & Africa
- GCC
- South Africa
- Rest of Middle East & Africa
- South America
- Brazil
- Argentina
- Rest of South America
- North America
Detailed Research Methodology and Data Validation
Primary Research
Mordor analysts interviewed gastroenterologists, community pharmacists, and payer advisors across North America, Europe, China, India, and Brazil. These discussions validated real-world prescription patterns, out-of-pocket self-medication rates, and the early uptake curve for vonoprazan, thereby closing gaps left by desk research and guiding final assumptions.
Desk Research
We collected prevalence and treatment data from public sources such as the World Health Organization Global Health Observatory, the CDC National Health Interview Survey, Eurostat health statistics, and Japan's National Health and Nutrition Survey. Drug utilization and pricing came from FDA Orange Book listings, EMA product information, UN Comtrade export codes for omeprazole and pantoprazole, and peer-reviewed meta-analyses indexed on PubMed. Market signals were further tracked through company 10-Ks and investor decks, supported by D&B Hoovers and Dow Jones Factiva for revenue splits. The sources cited are illustrative only and not exhaustive; many additional references informed our desk work.
Market-Sizing & Forecasting
A top-down prevalence-to-treated-patient model converts adult GERD incidence, treatment penetration, and average daily therapy cost into 2025 revenue. Results are corroborated with selective bottom-up channel checks on sampled PPI and antacid unit sales, which are then adjusted for parallel trade and private-label discounts. Key variables include obesity prevalence, aging-index shifts, over-the-counter antacid unit growth, regulatory approvals for novel PCABs, and forecast prescription days per patient. A multivariate regression projects these drivers through 2030 under baseline, optimistic, and restrained scenarios, followed by expert consensus weighting. Data gaps in bottom-up estimates are bridged with analog country proxies before final reconciliation.
Data Validation & Update Cycle
Outputs pass anomaly checks against independent import values, OTC panel data, and historic currency trends. A senior reviewer signs off after variance is within two percent. Reports refresh annually, with interim updates triggered by material events such as new drug launches or major guideline revisions.
Why Mordor's Gastroesophageal Reflux Disease Market Baseline Always Stays Dependable
Published estimates often diverge because each firm picks its own mix of drug classes, price corridors, and refresh timing.
Key gap drivers include narrow scopes that omit low-priced generics, aggressive discount assumptions that over-correct average selling prices, or conservative refresh cycles that still use pre-COVID prevalence. Mordor's frame captures OTC volumes, recent PCAB approvals, and region-specific payer mixes, letting our clients work with a grounded present-day figure.
Benchmark comparison
| Market Size | Anonymized source | Primary gap driver |
|---|---|---|
| USD 6.39 B (2025) | Mordor Intelligence | - |
| USD 5.11 B (2024) | Global Consultancy A | Excludes OTC antacids and uses constant 2020 price points |
| USD 5.24 B (2024) | Regional Consultancy B | Applies uniform treatment rate, ignores Asia obesity surge |
| USD 4.90 B (2024) | Industry Association C | Counts only prescription channels, omits self-medication spend |
The comparison shows that when variables, channels, and update cadence align with clinical reality, Mordor delivers a balanced and transparent baseline clients can retrace and replicate for confident decision-making.
Key Questions Answered in the Report
What is the current size of the Gastroesophageal Reflux Disease market?
The Gastroesophageal Reflux Disease market size is USD 6.39 billion in 2025 and is projected to reach USD 7.78 billion by 2030.
Which drug class holds the largest Gastroesophageal Reflux Disease market share?
Proton pump inhibitors dominate with 68.52% share in 2024, although their growth has slowed as potassium-competitive acid blockers gain momentum.
Why are potassium-competitive acid blockers viewed as game-changing?
PCABs such as vonoprazan provide faster, more consistent acid suppression and have demonstrated superior healing in PPI-refractory patients.
Which region is growing fastest in the Gastroesophageal Reflux Disease market?
Asia-Pacific posts the highest regional CAGR at 9.87%, driven by rising disposable income, dietary westernization, and expanding healthcare access.
How is telemedicine affecting GERD care delivery?
Telemedicine enables up to one-third of follow-up visits to shift to home-based video consultations, supporting rapid growth of the home-care end-user segment.
What is the primary restraint on future PPI sales?
Patent expirations and heightened FDA safety alerts are encouraging generic substitution and deprescribing, curbing long-term PPI revenue growth.
Page last updated on:
